Cropped 2.jpg

News Release

View printer-friendly version
<< Back
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2019 Financial Results

Consecutive year of record annual revenue with 26.0% year-over-year growth to $72.6 million

Full year 2020 revenue growth guidance in the range of 22% to 24%

WARSAW, Ind., March 04, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2019.

Fourth Quarter / Full Year 2019 & Recent Highlights                

  • Increased total revenue to $19.0 million for fourth quarter 2019, up 30.1% from $14.6 million in fourth quarter 2018, driving consecutive year of annual record setting revenue of $72.6 million for full year 2019, up from $57.6 million or 26.0% year-over-year
  • Generated Adjusted EBITDA of ($1.1) million for full year 2019, up from ($3.5) million in full year 2018
  • Increased the domestic sales organization to 167 consultants, up 27.5% from fourth quarter 2018
  • Deployed $18.2 million of consignment sets for full year 2019, up 51.7% compared to $12.0 million in the same period prior year
  • Launched PediFoot Deformity Correction System and QuickPack™ bone graft substitute in fourth quarter 2019 and expanded product portfolio offering to 33 surgical systems in 2019, up 27% from 26 in the fourth quarter 2018
  • Strengthened cash position with $60 million in net proceeds from follow-on offering in December 2019
  • Divested assets related to the adult product offering of our subsidiary, Vilex in Tennessee, Inc., in December 2019 and fully repaid debt facility used to finance the original acquisition
  • Provided full year 2020 revenue guidance of growth in the range of 22%-24% and investment in consignment sets to be in a range of $19-$21 million

Mark Throdahl, President and Chief Executive Officer of OrthoPediatrics, commented, “We are excited to report another record year of outperformance with 26% annual revenue growth that reflects systematic execution of all our growth initiatives.  During the fourth quarter, we continued to see strength across our entire business with Trauma and Deformity growing 34%, Scoliosis growing 21%, and Sports Medicine/Other growing 18%. We are pleased with our initial integration of Orthex and recent product launches, including PediFoot and QuickPack™ during the fourth quarter, and look forward to deeper penetration of the external fixation market and increased utilization of our product portfolio. We remain optimistic about the long-term contributions from the synergies unique to our product offering and will continue acquiring new technologies and introducing new systems to enhance our leadership position.”

Mr. Throdahl continued, “As we look ahead to 2020, we are confident in our ability to continue to execute on our growth initiatives that will support full year 2020 revenue guidance of 22% to 24%. We believe investing $19-$21 million in consigned sets for 2020 will allow us to focus on deploying capital-efficient systems and begin realizing the revenue impact from the full roll-out of our recent product launches. We appreciate the support of our shareholders that helped us close a $60 million capital raise that provides the Company financial flexibility to support our growth initiatives. We are pleased our commitment to pediatric-specific surgical solutions has allowed us to change the lives of over 165 thousand children since our inception, and we remain dedicated to driving increased value for all our stakeholders.”

Fourth Quarter and Full Year 2019 Financial Results
Total revenue for the fourth quarter of 2019 was $19.0 million, a 30.1% increase compared to $14.6 million for the same period last year. U.S. revenue for the fourth quarter of 2019 was $14.2 million, a 29.5% increase compared to $10.9 million for the same period last year, representing 74.7% of total revenue. International revenue for the fourth quarter of 2019 was $4.8 million, a 31.8% increase compared to $3.6 million for the same period last year, representing 25.3% of total revenue.

Total revenue for 2019 was $72.6 million, a 26.0% increase compared to $57.6 million for 2018. Our U.S. revenue for 2019 was $55.1 million, a 26.7% increase compared to $43.5 million for 2018, representing 75.9% of total revenue. Our international revenue for 2019 was $17.5 million, a 24.1% increase compared to $14.1 million for 2018, representing 24.1% of total revenue.

Trauma and Deformity revenue for the fourth quarter of 2019 was $13.6 million, a 34.3% increase compared to $10.2 million for the same period last year. Scoliosis revenue was $4.9 million, a 20.7% increase compared to $4.1 million for the fourth quarter of 2018. Sports Medicine/other revenue for the fourth quarter of 2019 was $430 thousand, a 17.8% increase compared to $365 thousand for the same period last year.

Trauma and Deformity revenue for 2019 was $49.4 million, a 24.4% increase compared to $39.7 million for 2018. Scoliosis revenue for 2019 was $21.5 million, a 28.9% increase compared to $16.7 million for 2018. Sports medicine/other revenue for 2019 was $1.7 million, a 41.1% increase compared to $1.2 million in 2018.

Gross profit for the fourth quarter of 2019 was $14.5 million, a 37.4% increase compared to $10.5 million for the same period last year, and $54.6 million for 2019, a 28.0% increase compared to $42.7 million for 2018. Gross profit margin for the fourth quarter of 2019 improved to 76.2%, compared to 72.2% for the same period last year, and was 75.3% for 2019, compared to 74.2% for 2018.  The increase is due to increased sales and a decrease in cost of goods sold related to the addition of sales agents in our international markets.

Total operating expenses for the fourth quarter of 2019 were $17.5 million, a 41.2% increase compared to $12.4 million for the same period last year. Full year operating expenses were $63.7 million for 2019, a 21.9% increase compared to $52.2 million for 2018. The increase in operating expenses for full year 2019 was driven by a 27.3% increase in general and administration, a 17.8% increase in sales and marketing, and a 21.5% increase in research and development. Operating loss for the fourth quarter of 2019 was ($3.0) million compared to ($1.9) million for the same period last year. Operating loss for 2019 was ($9.1) million compared to ($9.6) million for 2018.

Net interest expense for the fourth quarter of 2019 was $1.3 million, compared to $0.5 million for the same period last year, and was $3.5 million for 2019 compared to $2.3 million for 2018.

Net loss from continuing operations for the fourth quarter of 2019 was ($4.3) million, compared to ($2.5) million for the same period last year. Total net loss including discontinued operations for the fourth quarter of 2019 was ($5.4) million, or ($0.36) per basic and diluted share attributable to common stockholders, compared to ($2.5) million, or ($0.19) per basic and diluted share for the same period last year. Adjusted EBITDA for the fourth quarter of 2019 and 2018 was ($0.9) million.

Net loss from continuing operations for 2019 was ($12.7) million, compared to ($12.0) million for 2018. Total net loss including discontinued operations for the full year 2019 was ($13.7) million, or ($0.94) per basic and diluted share attributable to common stockholders for 2019, compared to ($12.0) million, or ($0.96) per basic and diluted share for 2018. Adjusted EBITDA for the full year 2019 was ($1.1) million from ($3.5) million for the full year 2018. See below for additional information and a reconciliation of non-GAAP financial information.

The weighted average number of diluted shares outstanding for the three-month period ended December 31, 2019 was 15,031,256 shares.

In the fourth quarter of 2019, we had 167 sales representatives, including representatives selling our Orthex products, up 27.5% compared to 131 in the same period of 2018.

The change in property and equipment during the fourth quarter of 2019 was $1.3 million, which compared to a reduction of $58 thousand for the same period last year, and $11.8 million for 2019, compared to $5.3 million for 2018. This investment reflects the deployment of consigned sets, which includes product specific instruments and cases and trays. Including the implants, $4.5 million of consigned sets were deployed during the fourth quarter of 2019, compared to $1.3 million during the fourth quarter of 2018.

As of December 31, 2019, cash, cash equivalents and restricted cash were $72.0 million, compared to $19.7 million as of September 30, 2019, and the Company had approximately $26.2 million in total outstanding indebtedness, which includes $5.0 million outstanding under its revolving credit facility.

Capitalization Update
On December 11, 2019, the Company completed a public offering selling 1,755,500 shares at a price of $36.50 per share, including 235,500 shares sold to the underwriters upon exercise of the option to purchase additional shares. The public offering generated net proceeds of $60 million, after deducting underwriting commissions and offering expenses payable by OrthoPediatrics.

On December 31, 2019, the Company completed the sale of substantially all of the assets related to the adult product offering of Vilex in Tennessee, Inc (“Vilex Adult Business”), as well as a license to sell the Orthex hexapod into the adult foot and ankle marketplace to Vilex LLC, an affiliate of Squadron Capital LLC (“Squadron Capital”). As consideration for the Vilex Adult Business and the Orthex license, the amount owed by OrthoPediatrics under its Term Note B payable to Squadron Capital was reduced by $25.0 million. The Company repaid in full the remaining $5.0 million of principal outstanding under the Term Note B, plus all accrued interest, on December 31, 2019, with funds received from its revolving credit facility with Squadron Capital.

Full Year 2020 Financial Guidance
OrthoPediatrics is providing financial guidance for the full year 2020, as follows:

  • Revenue growth in a range of 22% to 24% year-over-year
  • Consigned set investments in a range of $19.0 million to $21.0 million

Conference Call
OrthoPediatrics will host a conference call on Thursday, March 5, 2020, at 8:00 a.m. ET to discuss the results. The dial-in numbers are (855) 289-4603 for domestic callers and (614) 999-9389 for international callers. The conference ID number is 7662677. A live webcast of the conference call will be available online from the investor relations page of the OrthoPediatrics’ corporate website at www.orthopediatrics.com.

A replay of the webcast will remain available on OrthoPediatrics’ website, www.orthopediatrics.com, until the Company releases its first quarter 2020 financial results. In addition, a telephonic replay of the call will be available until March 12, 2020. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 7662677.

Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential,” "objective," "would" and other similar expressions. Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics’ control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others, the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 7, 2019, as updated and supplemented by our other SEC reports filed from time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net loss from continuing operations, plus interest expense, net plus other expense, depreciation and amortization, stock-based compensation expense, accelerated vesting of restricted stock upon our IPO, and acquisition related costs. Adjusted EBITDA is presented because the Company believes it is a useful indicator of its operating performance. Management uses the metric as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes this measure is useful to investors as supplemental information because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using Adjusted EBITDA on a supplemental basis. The Company’s definition of this measure is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain a reconciliation of Net Loss from continuing operations to non-GAAP Adjusted EBITDA.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 33 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com


ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 (In Thousands, Except Share Data)

    December 31, 2019   December 31, 2018  
           
ASSETS
Current assets:          
Cash   $  70,777     $    60,691    
Restricted cash       1,250         -     
Accounts receivable - trade, less allowance for doubtful accounts of $506 and $134, respectively       16,003         8,999    
Inventories, net       38,000         25,708    
Notes receivable       564         502    
Prepaid expenses and other current assets       1,464         1,256    
Total current assets       128,058         97,156    
           
Property and equipment, net       21,349         12,768    
           
Other assets:          
Amortizable intangible assets, net       14,484         1,921    
Goodwill       26,183         -    
Other intangible assets       4,490         260    
Total other assets       45,157         2,181    
           
Total assets   $    194,564     $    112,105    
           
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:          
Accounts payable - trade   $    6,467     $    3,971    
Accrued compensation and benefits       4,349         3,552    
Current portion of long-term debt with affiliate       124         118    
Other current liabilities       2,723         1,576    
Total current liabilities       13,663         9,217    
           
Long-term liabilities:          
Long-term debt with affiliate, net of current portion       26,067         21,156    
Operating lease liabilities       63         -    
Deferred revenue       12,410         -    
Total long-term liabilities       38,540         21,156    
           
Total liabilities       52,203         30,373    
           
Stockholders' equity:          
Common stock, $0.00025 par value; 50,000,000 shares authorized; 16,723,128 shares and 14,538,202 shares issued and outstanding as of December 31, 2019 and December 31, 2018       4         4    
Additional paid-in capital       271,182         197,442    
Accumulated deficit       (128,822 )       (115,091 )  
Accumulated other comprehensive loss       (3 )       (623 )  
Total stockholders' equity       142,361         81,732    
           
Total liabilities and stockholders' equity   $    194,564     $    112,105    


ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)

  Three Months Ended December 31,   Year Ended December 31,
  2019   2018   2019   2018
Net revenue $    18,952     $    14,568     $  72,552     $    57,559  
Cost of revenue   4,502       4,054         17,933         14,879  
Gross profit     14,450       10,514         54,619         42,680  
               
Operating expenses:              
Sales and marketing     8,360         6,558         31,284         26,563  
General and administrative     7,216       4,545         26,664         20,938  
Research and development     1,905       1,277         5,748         4,732  
Total operating expenses     17,481       12,380         63,696         52,233  
               
Operating loss     (3,031 )      (1,866 )       (9,077 )       (9,553 )
               
Other expenses:              
Interest expense, net     1,306       533         3,538         2,255  
Other expense (income)     (8 )     69       70         217  
Total other expenses     1,298       602         3,608         2,472  
               
Net loss from continuing operations   (4,329 )      (2,468 )     (12,685 )     (12,025 )
Net loss from discontinued operations, net of tax   (1,100 )     -       (1,046 )     -  
Net loss $  (5,429 )   $    (2,468 )   $   (13,731 )   $    (12,025 )
Net loss attributable to common stockholders $  (5,429 )   $  (2,468 )   $   (13,731 )   $   (12,025 )
Weighted average common shares – basic and diluted     15,031,256         13,010,761         14,624,194         12,567,387  
Net loss from continuing operations per share attributable to common stockholders – basic and diluted $    (0.29 )   $    (0.19 )   $    (0.87 )   $  (0.96 )
Net loss from discontinued operations per share attributable to common stockholders – basic and diluted   (0.07 )     -       (0.07 )     -  
Net loss per share attributable to common stockholders – basic and diluted $    (0.36 )   $    (0.19 )   $    (0.94 )   $    (0.96 )


ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands)

  For the Year Ended December 31,
    2019       2018  
OPERATING ACTIVITIES              
Net loss  $    (13,731 )   $    (12,025 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Loss on sale of discontinued operations     210         -  
Depreciation and amortization     4,671         2,892  
Stock-based compensation     2,603         3,185  
Changes in certain current assets and liabilities:      
Accounts receivable – trade     (5,820 )       (3,801 )
Inventories     (9,767 )       (4,801 )
Prepaid expenses and other current assets     (137 )       (425 )
Accounts payable - trade     2,401         (1,524 )
Accrued expenses and other liabilities     1,946         947  
Other     (1 )       (31 )
Net cash used in operating activities – continuing operations     (17,625 )       (15,583 )
Net cash used in operating activities – discontinued operations   (144 )     -  
Net cash used in operating activities   (17,769 )     (15,583 )
       
INVESTING ACTIVITIES      
Acquisition of Vilex, net of cash acquired     (49,836 )       -  
Purchases of notes receivable     -         (502 )
Purchases of licenses     (270 )       (210 )
Purchases of property and equipment     (11,816 )       (5,253 )
Net cash used in investing activities     (61,922 )       (5,965 )
       
FINANCING ACTIVITIES      
Proceeds from issuance of debt with affiliate   30,000       -  
Payment of revolving credit facility with affiliate     -         (4,065 )
Proceeds from issuance of common stock, net of issuance costs     59,996         43,425  
Proceeds from exercise of stock options     1,141         410  
Payments on mortgage notes     (118 )       (113 )
Net cash provided by financing activities     91,019         39,657  
       
Effect of exchange rate changes on cash   8       -  
       
NET INCREASE IN CASH     11,336         18,109  
       
Cash, beginning of year     60,691         42,582  
Cash and restricted cash, end of period $    72,027     $    60,691  
       
SUPPLEMENTAL DISCLOSURES      
Cash paid for interest $    4,229     $    2,255  
Transfer of instruments from property and equipment to inventory $    1,037     $    362  
Acquisition consideration of common shares $    10,000     $ -  
Intellectual property license $   12,410     $ -  
Divestiture consideration allocated to assets held for sale $   12,590     $ -  
Payment of Term Note B with revolving credit facility $   5,000     $ -  


ORTHOPEDIATRICS CORP.
NET REVENUE BY GEOGRAPHY AND PRODUCT CATEGORY
(Unaudited)
(In Thousands)

  Three Months Ended December 31,   Year Ended December 31,
Product sales by geographic location: 2019   2018   2019   2018
U.S. $   14,155   $   10,929   $   55,055   $   43,461
International     4,797       3,639       17,497       14,098
Total $   18,952   $   14,568   $   72,552   $   57,559
               
  Three Months Ended December 31,   Year Ended December 31,
Product sales by category: 2019   2018   2019   2018
Trauma and deformity $   13,631   $   10,150   $   49,371   $   39,695
Scoliosis   4,891     4,053     21,485     16,662
Sports medicine/other   430     365     1,696     1,202
Total $   18,952   $   14,568   $   72,552   $   57,559


ORTHOPEDIATRICS CORP.
RECONCILIATION OF NET LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA
(Unaudited)
(In Thousands)

  Three Months Ended December 31,   Year Ended December 31,
  2019   2018   2019   2018
Net loss from continuing operations $    (4,329 )   $   (2,468 )   $    (12,685 )   $   (12,025 )
Interest expense, net    1,306        533         3,538         2,255  
Other expense    (8 )      69         70         217  
Depreciation and amortization    1,405        715         4,671         2,892  
Stock-based compensation    707        287         2,603         1,199  
Accelerated vesting of restricted stock upon our IPO    -         -          -          1,986  
Acquisition related costs    -         -          737         -   
Adjusted EBITDA $   (919 )   $   (864 )   $   (1,066 )   $   (3,476 )

ortho.jpg

Source: OrthoPediatrics Corp.